3D-printed flexible-dose HIV medicine for children
Official title: Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
Funded at Texas A&m University Health Science Ctr · NIH-11365779 · Data updated 2026-11-12
Making 3D-printed, dose-adjustable HIV combination medicines so children can get the right dose more easily.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $543,324 |
| NIH project number | 5R01HD112077-04 |
| Project ID | NIH-11365779 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children living with HIV who need TDF-3TC combination therapy—particularly those in the pediatric age range for these drugs (about 2–12 years) and their caregivers—are the ideal candidates.
✕Less likely to help
Adults, children who require different antiretroviral regimens, or patients with allergies to the study drugs would likely not benefit from these specific formulations.
What this research studies
This project uses 3D printing to create solid combination tablets of tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) with adjustable doses for children. Researchers will develop printable formulations that pharmacists can prepare in a hospital setting and will test them for dose accuracy, stability, sterility, and how the drugs are absorbed. The team will compare printed products to current compounded pediatric preparations to ensure safety and consistency. Work is planned for deployment at Driscoll Children’s Hospital to create practical workflows for clinical use.
Why it matters
Potential benefit: If successful, children with HIV could have easier-to-dose, more consistent combination pills that improve adherence and treatment outcomes.
How similar studies have gone: 3D printing has been used to make individualized drug forms (including an FDA-approved 3D-printed epilepsy medicine), but printed dose-tailored TDF-3TC pediatric combinations are a newer and largely untested application.
Where this research is happening
-
Texas A&m University Health Science Ctr
College Station, United States Active
Researchers
- Principal investigator: Khan, Mansoor a — Texas A&m University Health Science Ctr
- Study coordinator: Khan, Mansoor a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.